Abstract Objective To study the pharmacokinetic and pharmacodynamic features of different doses of aminophylline in very low birth weight (VLBW) infants with different postmenstrual ages, weights, and ages (in days). Methods A total of 40 VLBW infants with apnea were enrolled. After an intravenous loading dose of 5 mg/kg aminophylline, they were randomized into two groups with different maintenance doses of aminophylline (1 mg/kg and 2 mg/kg, once every 8 hours). Blood concentrations of aminophylline and liver and renal functions were monitored at 8 hours, 3 days, and 7 days after the loading dose. Attacks of apnea were documented. Pharmacokinetic data of aminophylline were compared between the two groups. Results The steady-state plasma concentration of aminophylline and plasma clearance in the 2 mg/kg group were significantly higher than those in the 1 mg/kg group (P<0.05). However, the elimination half life was shorter in the 2 mg/kg group (P<0.05). Days of apnea attacks within 7 days after birth in the 2 mg/kg group were significantly fewer than in the 1 mg/kg group (P<0.05). Aminophylline plasma clearance was positively correlated with age (in days) after birth and postmenstrual age in both groups. Conclusions In VLBW infants, pharmacokinetics and pharmacodynamics are different when different maintenance doses of aminophylline are given. The maintenance dose of 2 mg/kg is associated with a better effect in the treatment of apnea. Postmenstrual age and age (in days) should be considered during the adjustment of dose, and routine blood concentration monitoring should be performed.
About author:: 10.7499/j.issn.1008-8830.2015.11.005
Cite this article:
YANG Xiao-Yan,ZHAO Jing,SHI Jing et al. Investigation of pharmacokinetics and pharmacodynamics of different doses of aminophylline in very low birth weight infants[J]. CJCP, 2015, 17(11): 1171-1175.
YANG Xiao-Yan,ZHAO Jing,SHI Jing et al. Investigation of pharmacokinetics and pharmacodynamics of different doses of aminophylline in very low birth weight infants[J]. CJCP, 2015, 17(11): 1171-1175.
Schmidt B, Roberts RS, Davis P, et al. Caffeine therapy for apnea of prematurity[J]. N Eng J Med, 2006, 354(20): 2112-2121.
[2]
Zhao J, Gonzalez F, Mu DZ. Apnea of prematurity: from cause to treatment[J]. Eur J Pediatr, 2011, 170(9): 1097-1105.
[3]
Armanian AM, Badiee Z, Afghari R, et al. Prophylactic aminophylline for prevention of apnea at higher-risk preterm neonates[J]. Iran Red Crescent Med J, 2014, 16(8): e12559.
[4]
Schmidt B, Roberts RS, Davis P, et al. Long-term effects of caffeine therapy for apnea of prematurity[J]. N Eng J Med, 2007, 357(19): 1893-1902.
[5]
Butler TJ, Firestone KS, Grow JL, et al. Standardizing documentation and the clinical approach to apnea of prematurity reduces length of stay, improves staff satisfaction, and decreases hospital cost[J]. Jt Comm J Qual Patient Saf, 2014, 40(6): 263-269.
Kumral A, Tuzun F, Yesilirmak DC, et al. Genetic basis of apnoea of prematurity and caffeine treatment response: role of adenosine receptor polymorphisms: genetic basis of apnoea of prematurity[J]. Acta Paediatr, 2012, 101(7): e299-e303.
Proost JH, Meijer DK. MW/Pharm, an integrated software package for drug dosage regimen calculation and therapeutic drug monitoring[J]. Comput Biol Med, 1992, 22(3): 155-163.
[15]
Bennett JE, Wakefield JC. A comparison of a Bayesian population method with two methods as implemented in commercially available software[J]. J Harmacokinet Biopharm, 1996, 24(4): 403-432.
